GenAI-assisted RA bone erosion risk and DMARD choice

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this prospective, single-arm study, physicians use GenAI-assisted clinical decision support to help determine RA bone erosion risk and select DMARDs during routine inpatient care. The study focuses on newly diagnosed RA patients admitted to Guang’anmen Hospital in Beijing. Researchers will document physicians’ initial risk assessments and treatment choices with and without GenAI input to evaluate feasibility and potential impact in real-world practice.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Newly diagnosed RA patients meeting American College of Rheumatology / European League Against Rheumatism 2010 classification criteria
* Consecutive inpatients admitted during study period

Exclusion Criteria:

* Patients subsequently determined not to have RA
* Incomplete clinical data preventing risk or treatment assessment

Where it's running

• Guang'anmen Hospital of China Academy of Chinese Medical Sciences
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Quan Jiang, MD
• Email: doctorjq@126.com
• Phone: 010-88001942

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pain patterns in rheumatic diseases: see if pain works differently in patients and healthy people

  This observational study tests how pain is experienced and measured in people with rheumatic diseases compared with healthy volunteers.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07829497

• Telitacicept for difficult-to-treat rheumatoid arthritis

  This study tests whether adding telitacicept to standard therapy helps adults with hard-to-treat rheumatoid arthritis see better control of their symptoms.

  Recruiting Phase 2 Peking University People's Hospital · Hefei, Anhui and 46 other locations · NCT07796516

• PTC844 in people with active rheumatoid arthritis

  This study tests whether PTC844 is safe and how it behaves in the body compared with placebo for people with active rheumatoid arthritis.

  Recruiting at 6 sites Phase 2 PTC Therapeutics · Chandler, Arizona and 25 other locations · NCT07779616

• First-in-human test of CND319 in healthy people and people with rheumatic diseases

  This early study tests whether CND319 is safe and tolerable and whether it shows any signs of activity in healthy adults and in people with rheumatoid arthritis or Sjogren's syndrome.

  Recruiting Phase 1 Candid Therapeutics · Melbourne, Victoria · NCT07712939

• IV sarilumab for adults with rheumatoid arthritis

  This study tests IV sarilumab to see how it works and how safe it is for adults with moderately to severely active rheumatoid arthritis, with or without certain standard arthritis medicines.

  Recruiting at 12 sites Phase 1/2 Sanofi · Centennial, Colorado and 11 other locations · NCT07704580

• Tipmed Shoulder Prosthesis PMCF: safety and outcomes after shoulder replacement

  This PMCF study tests the safety and function of the Tipmed shoulder prosthesis in adults undergoing reverse shoulder or hemiarthroplasty in real-world practice.

  Recruiting TIPMED Medical Device Manufacturing Ltd. Co. · Balıkesir and 3 other locations · NCT07678034

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.